LC3-associated phagocytosis is impaired in monocyte-derived macrophages from systemic sclerosis patients
Quentin Frenger(Inserm), Frédéric Gros(Inserm), Stéphane Giorgiutti(Inserm), Philippe Mertz(Inserm), Aurélien Guffroy(Inserm), Yannick Dieudonné, Nadège Wadier(Inserm), Anne‐Sophie Korganow(Inserm), Renaud Felten(Centre National de la Recherche Scientifique), Sabine Depauw(Inserm), Arthur Petitdemange(Inserm), Emmanuel Chatelus(Immune Regulation (United Kingdom)), Jean Sibilia(Inserm), Laurent Arnaud(Inserm), Julie A. Lucas(Inserm), Thierry Martin(Western Infirmary), Luisa Path(Centre National de la Recherche Scientifique), Léa Jaquel(Immune Regulation (United Kingdom)), Hélène Merlin(Hôpitaux Universitaires de Strasbourg), Mathilde Herber(Immune Regulation (United Kingdom)), Vincent Poindron(Inserm), Ya-Zhuo Gong(Hôpitaux Universitaires de Strasbourg), Jacques‐Eric Gottenberg(Inserm), A Meyer(Hôpitaux Universitaires de Strasbourg)
Cited by 0
Related Papers
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
<i>MUC5B</i> Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease
|New England Journal of Medicine|2018|501
A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)
|Annals of the Rheumatic Diseases|2016|355
2021 DORIS definition of remission in SLE: final recommendations from an international task force
|Lupus Science & Medicine|2021|340